The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
 
Stephanie Pei Li Saw
Honoraria - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Pfizer (Inst)
Speakers' Bureau - AstraZeneca (Inst); MSD Oncology (Inst)
Research Funding - AstraZeneca; Guardant Health
Travel, Accommodations, Expenses - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); MSD; MSD (Inst)
 
Yi Fen Low
No Relationships to Disclose
 
Gillianne Lai
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - Amgen
Research Funding - AstraZeneca (Inst); Bristol-Myers-Squibb (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst)
 
Landon Chan
No Relationships to Disclose
 
Wesley K. Y. Wong
No Relationships to Disclose
 
Giselle Tsui
No Relationships to Disclose
 
Olivia Chen
No Relationships to Disclose
 
Amanda Oon Lim Seet
No Relationships to Disclose
 
Wei Chong Tan
No Relationships to Disclose
 
Aaron C. Tan
Honoraria - Amgen; AstraZeneca; Guardant Health AMEA; Janssen; Juniper Biologics; Pfizer; Roche; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Bayer; Pfizer
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - ASLAN Pharmaceuticals; Illumina
 
Johan W.K. Chan
Honoraria - Bayer; Merck (Inst); Pfizer (Inst)
Consulting or Advisory Role - Bayer; MSD Oncology (Inst)
 
Yi Lin Teh
Consulting or Advisory Role - Novartis
 
Wan Ling Tan
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Ipsen (Inst); MSD (Inst)
 
Quan Sing Ng
Research Funding - Bayer (Inst); BMS (Inst)
 
Mei-Kim Ang
No Relationships to Disclose
 
Ravindran Kanesvaran
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD Oncology; Novartis
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Janssen Oncology; MSD Oncology; Novartis; pfizer
Research Funding - Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; MSD Oncology
 
Darren Wan-Teck Lim
No Relationships to Disclose
 
Daniel Shao-Weng Tan
Honoraria - Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); DKSH (Inst); Genmab; Merck (Inst); Pfizer (Inst); Roche (Inst); Zymeworks
Research Funding - ACM Biolabs (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Aurora Tele-Oncology Platform; HUTCHMED; Insighta Holdings Limited
Stock and Other Ownership Interests - Alentis Therapeutics; AstraZeneca; Aurora Tele-Oncology Platform; Biolidics; D3 Bio; HUTCHMED; Lunit; Prenetics
Honoraria - Abbvie; ACEA Pharmaceutical Research; Adagene; Alpha Biopharma; Amgen; Amoy Diagnostics; AnHeart Therapeutics; AstraZeneca; AVEO; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CStone Pharmaceuticals; Curio Science; D3; Da Volterra; Daiichi Sankyo/UCB Japan; Daz Group; Eisai; Fishawack Facilitate; Gilead Sciences; GLG’s Healthcare; Gritstone Bio; Guardant Health; Hengrui Therapeutics; Ignyta; Illumina; Incyte; Inivata; InMed; IQVIA; Janssen; Jiahui Holdings Co; Lakeshore Biotechnology; Lilly; Lucence; Lucence; MD Health Brazil,; Medscape; Merck; Merck Sharp & Dohme; MiRXES; Novartis; Novocure; Omega Therapeutics; Origimed; PeerVoice; Permanyer Publications; Pfizer; Physicans' Education Resource; Prenetics; Prime Oncology; Qiming Development (HK) Ltd.; Regeneron; Research to Practice; Roche; Sanofi Aventis GmbH; SFJ Pharmaceutical Ltd; Shanghai BeBirds Translation & Consulting; Shanghai Promedican Pharmaceuticals Co., Ltd; Simcere of America Inc.; Summit Therapeutics Sub, Inc.; Suzhou Liangyihui Network Technology; Synergy Research; Taiho Pharmaceutical; Takeda; Tigermed; touchIME; Vertex; Virtus Medical Group; Xencor; Yuhan
Consulting or Advisory Role - Abbvie; ACEA Pharmaceutical Research; Adagene; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; Bayer HealthCare Pharmacuticals; BeiGene; BerGenBio; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bowtie Life Insurance Company; Bridgebio; Bristol-Myers Squibb; C4 Therapeutics; Cirina; Covidien/Medtronic; Covidien/Medtronic; CStone Pharmaceuticals; Curio Science; D3; Da Volterra; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Fishawack Facilitate; G1 Therapeutics; geneDecode; Genentech; Gilead Sciences; Gritstone Bio; Guardant Health; Hengrui Therapeutics; HUTCHMED; Ignyta; Imagene AI Ltd.; Incyte; Inivata; IQvia; Janssen; Lakeshore Biotechnology; Lilly; Loxo; Lucence; Lunit; Medtronic; Merck Serono; Merck Sharp & Dohme; Mirati Therapeutics; MiRXES; Novartis; Omega Therapeutics; OrigiMed; OSE Immunotherapeutics; Pfizer; Prenetics; PrIME Oncology; Puma Biotechnology; Qiming Development (HK) Ltd.; Regeneron; Roche; SFJ Pharmaceuticals Group; Simcere; Summit Therapeutics; Synergy Research; Takeda; Tigermed; Vertex; Virtus Medical Group; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Takeda (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Abbvie; Astrazeneca; Daiichi Sankyo; Liangyihui; MiRXES; Novartis; Pfizer; Pfizer; Roche; Zai Lab
 
Molly SC Li
Honoraria - ACE oncology; Amgen; Anheart Therapeutics; AstraZeneca; Gilead Sciences; Janssen; Novartis; Pfizer; Takeda; Zai Lab
Consulting or Advisory Role - Amgen; Anheart Therapeutics; Pfizer; Takeda; Yuhan; Zai Lab
Research Funding - AstraZeneca; Gilead Sciences; MSD Oncology
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/UCB Japan; Pfizer; Roche; Zai Lab